Amneal Pharmaceuticals (AMRX) Cash from Investing Activities (2017 - 2026)

Amneal Pharmaceuticals' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$21.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 21.98% year-over-year to -$21.7 million; the TTM figure through Mar 2026 stood at -$116.2 million (down 90.34% YoY), while the FY2025 annual figure was -$112.3 million, down 78.21% from the prior year.
• Cash from Investing Activities was -$21.7 million for Q1 2026 at Amneal Pharmaceuticals, up from -$45.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$6.5 million in Q2 2024 to a low of -$97.4 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$25.9 million across 5 years, with a median of -$19.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 667.31% in 2022, then jumped 87.95% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$11.5 million in 2022, then tumbled by 176.4% to -$31.7 million in 2023, then soared by 49.33% to -$16.1 million in 2024, then slumped by 183.04% to -$45.5 million in 2025, then surged by 52.24% to -$21.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$21.7 million (Q1 2026), -$45.5 million (Q4 2025), and -$22.5 million (Q3 2025), per Business Quant data.